Lynx1 Capital Management as of Sept. 30, 2025
Portfolio Holdings for Lynx1 Capital Management
Lynx1 Capital Management holds 14 positions in its portfolio as reported in the September 2025 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price |
|---|---|---|---|---|---|
| Merus N V (MRUS) | 29.4 | $144M | 1.5M | 94.15 | |
| Stoke Therapeutics (STOK) | 22.4 | $110M | 5.4M | 20.33 | |
| Gh Research Ordinary Shares (GHRS) | 21.2 | $104M | 8.6M | 12.13 | |
| Protagonist Therapeutics (PTGX) | 9.5 | $47M | 700k | 66.43 | |
| Cullinan Oncology (CGEM) | 7.0 | $34M | 5.8M | 5.93 | |
| C4 Therapeutics Com Stk (CCCC) | 3.2 | $16M | 7.1M | 2.22 | |
| Tscan Therapeutics (TCRX) | 2.9 | $14M | 7.9M | 1.82 | |
| Precision Biosciences Com New (DTIL) | 1.2 | $5.8M | 1.0M | 5.52 | |
| Adc Therapeutics Sa SHS (ADCT) | 1.1 | $5.3M | 1.3M | 4.00 | |
| Passage Bio Com New (PASG) | 1.0 | $5.0M | 624k | 8.03 | |
| Denali Therapeutics (DNLI) | 0.8 | $3.8M | 262k | 14.52 | |
| Ibio Com New (IBIO) | 0.2 | $874k | 1.1M | 0.83 | |
| Allogene Therapeutics (ALLO) | 0.1 | $677k | 546k | 1.24 | |
| Design Therapeutics (DSGN) | 0.1 | $497k | 66k | 7.53 |
